Late Breaking Abstract - LUSTER-1 and -2: randomised controlled trials of fevipiprant in severe asthma
Sign Up to like & getrecommendations! Published in 2020 at "European Respiratory Journal"
DOI: 10.1183/13993003.congress-2020.4614
Abstract: Introduction: Fevipiprant, an oral, non-steroidal, highly selective, reversible antagonist of the PGD2 receptor 2, improved lung function and sputum eosinophil counts in asthma patients in Phase II clinical trials. Aim: To determine whether fevipiprant reduces… read more here.
Keywords: severe asthma; trials fevipiprant; placebo; controlled trials ... See more keywords